We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novavax has begun preclinical testing of intranasal versions of its avian influenza vaccines, providing a potential alternative to administering these vaccines by injection.
Bayer announced that a head-to-head study comparing the company's drug Levitra (vardenafil) with Viagra (sildenafil) in patients with erectile dysfunction and risk factors for cardiovascular disease shows that in those men who expressed a preference, 53 percent preferred vardenafil compared with 47 percent who preferred sildenafil.
MediGene has announced that the interim analysis of the Phase I/II trial of the cancer-killing virus NV1020 for the treatment of liver metastases in patients suffering from colorectal carcinoma has shown a clear indication of efficacy.
Ecopia BioSciences announced it has received a "no objection" letter from the Therapeutics Products Directorate of Health Canada for the amendment to the ongoing Phase I clinical trial related to the company's anti-cancer agent, ECO-4601, allowing for the inclusion of pancreatic cancer patients.
Acrux announced it will soon begin a Phase II trial in the U.S. following the recent FDA acceptance of an investigational new drug application for Testosterone MD-Lotion.
Nymox Pharmaceutical has announced positive efficacy and safety results from its recently completed Phase II trial of NX-1207 for benign prostatic hyperplasia (BPH).